abatacept SC
Selected indexed studies
- Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. (N Engl J Med, 2020) [PMID:33053283]
- Enhancement of antitumor immunity by CTLA-4 blockade. (Science, 1996) [PMID:8596936]
- Long-Term Immunosuppression Management: Opportunities and Uncertainties. (Clin J Am Soc Nephrol, 2021) [PMID:33853841]
_Worker-drafted node — pending editorial review._
Connections
abatacept SC is a side effect of
Sources
- Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. (2020) pubmed
- Abatacept dose-finding phase II triaL for immune checkpoint inhibitors myocarditis (ACHLYS) trial design. (2025) pubmed
- Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled Trial. (2025) pubmed
- Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial. (2023) pubmed
- Enhancement of antitumor immunity by CTLA-4 blockade. (1996) pubmed
- Long-Term Immunosuppression Management: Opportunities and Uncertainties. (2021) pubmed
- Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. (2021) pubmed
- Juvenile Idiopathic Arthritis. (2017) pubmed
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. (2020) pubmed
- T cells specific for α-myosin drive immunotherapy-related myocarditis. (2022) pubmed